Skip to main content

Advertisement

SpringerLink
Log in

Outcome of surgery for ileojejunal neuroendocrine tumors

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

Neuroendocrine tumors (NET) of the ileum/jejunum are rare and may require different treatment options to provide long-term survival. The purpose of the study was to evaluate the outcome of surgery for ileojejunal NET.

Methods

A database of patients that underwent surgery for ileojejunal NETs between 1999 and 2010 was retrospectively analyzed regarding the clinical characteristics, surgical therapy, survival and prognostic factors.

Results

Only six of 97 patients with ileojejunal NET who underwent surgery had localized tumors (stage I/II), 29 had lymph node involvement (stage III) and 62 had distant metastases (stage IV) at the initial presentation. All stage I/II tumors were cured, in comparison to 69 % of stage III and 0 % of stage IV tumors (p = 0.01). Palliative surgery in combination with sequential multimodal treatment regimens resulted in a 5-year survival rate of 63 % in patients with stage IV tumors. A multivariate analysis showed that incomplete resection (HR 2.87; CI 1.18–6.98; p = 0.04) and distant metastases (HR 5.39; 95 % CI 1.23–23.57; p = 0.02) were associated with worse disease-specific survival.

Conclusions

Localized and regionally restricted ileojejunal NETs have an excellent prognosis after surgical treatment. Although stage IV tumors cannot be cured, an aggressive surgical approach in combination with medical or interventional treatment can provide long-term survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.

    Article  PubMed  Google Scholar 

  2. Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol. 2010;105(12):2563–9.

    Google Scholar 

  3. Modlin IM, Champaneria MC, Chan AK, Kidd M. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroenterol. 2007;102(7):1464–73.

    Article  PubMed  Google Scholar 

  4. Rivadeneira DE, Tuckson WB, Naab T. Increased incidence of second primary malignancy in patients with carcinoid tumors: case report and literature review. J Natl Med Assoc. 1996;88:310–2.

    PubMed  CAS  Google Scholar 

  5. Brune M, Gerdes B, Koller M, Rothmund M. Neuroendocrine tumors of the gastrointestinal tract (NETGI) and second primary malignancies–which is dominant? Dtsch Med Wochenschr. 2003;128(46):2413–7.

    Article  PubMed  CAS  Google Scholar 

  6. Soga J. Carcinoids of the small intestine: a statistical evaluation of 1102 cases collected from the literature. J Exp Clin Cancer Res 1997;16:353–63.

    Google Scholar 

  7. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, PROMID Study Group, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656–63.

    Article  PubMed  CAS  Google Scholar 

  8. Yantiss RK, Odze RD, Farraye FA, Rosenberg AE. Solitary versus multiple carcinoid tumors of the ileum: a clinical and pathologic review of 68 cases. Am J Surg Pathol. 2003;27(6):811–7.

    Article  PubMed  Google Scholar 

  9. Burke AP, Thomas RM, Elsayed AM, Sobin LH. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer. 1997;79(6):1086–93.

    Article  PubMed  CAS  Google Scholar 

  10. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79:813–29.

    Article  PubMed  CAS  Google Scholar 

  11. Godwin JD II. Carcinoid tumors: an analysis of 2,837 cases. Cancer. 1975;36:560–9.

    Article  PubMed  Google Scholar 

  12. Modlin IM, Gustafsson BI, Pavel M, Svejda B, Lawrence B, Kidd M. A nomogram to assess small-intestinal neuroendocrine tumor (‘carcinoid’) survival. Neuroendocrinology. 2010;92(3):143–57.

    Article  PubMed  CAS  Google Scholar 

  13. Plöckinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, European Neuroendocrine Tumor Society, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors. A consensus statement on behalf of the European Neuroendocrine Tumor Society (ENETS). Neuroendocrinology. 2004;80(6):394–424.

    Article  PubMed  Google Scholar 

  14. Klöppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O et al. European Neuroendocrine Tumor Society. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology;2009;90 (2162–6).

    Google Scholar 

  15. Akerström G, Hellman P, Hessman O, Osmak L. Management of midgut carcinoids. J Surg Oncol. 2005;89(3):161–9.

    Article  PubMed  Google Scholar 

  16. Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman TF, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on cancer (IARC), 2010. p. 13.

  17. Cunningham JL, Díaz de Ståhl T, Sjöblom T, Westin G, Dumanski JP, Janson ET. Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Genes Chromosom Cancer. 2011;50(2):82–94.

    Article  PubMed  CAS  Google Scholar 

  18. Modlin IM, Latich I, Zikusoka M, Kidd M, Eick G, Chan AK. Gastrointestinal carcinoids: the evolution of diagnostic strategies. J Clin Gastroenterol. 2006;40(7):572–82.

    Article  PubMed  Google Scholar 

  19. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128(6):1717–51.

    Article  PubMed  Google Scholar 

  20. Landerholm K, Zar N, Andersson RE, Falkmer SE, Järhult J. Survival and prognostic factors in small bowel carcinoid tumour. Br J Surg. 2011;98(11):1617–24.

    Article  PubMed  CAS  Google Scholar 

  21. Maggard MA, O′Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg. 2004;240(1):117–22.

    Article  PubMed  Google Scholar 

  22. Norlén O, Stålberg P, Oberg K, Eriksson J, Hedberg J, Hessman O. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg. 2012;36(6):1419–31.

    Article  PubMed  Google Scholar 

  23. Kimura W, Tezuka K, Hirai I. Surgical management of pancreatic neuroendocrine tumors. Surg Today. 2011;41(10):1332–43.

    Article  PubMed  Google Scholar 

  24. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, RADIANT-2 Study Group, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005–12.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Surgery, University Hospital Marburg, Baldingerstraße, 35043, Marburg, Germany

    Nils Habbe, Volker Fendrich, Anna Heverhagen & Detlef K. Bartsch

  2. Institute of Pathology, University Hospital Marburg, Marburg, Germany

    Annette Ramaswamy

Authors
  1. Nils Habbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Volker Fendrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Heverhagen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Annette Ramaswamy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Detlef K. Bartsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Volker Fendrich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Habbe, N., Fendrich, V., Heverhagen, A. et al. Outcome of surgery for ileojejunal neuroendocrine tumors. Surg Today 43, 1168–1174 (2013). https://doi.org/10.1007/s00595-012-0408-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-012-0408-1

Keywords

Search

Navigation